Last updated: February 24, 2026
What is the scope of Cyprus patent CY1122054?
CY1122054 pertains to a pharmaceutical invention aimed at treatment or prevention of a specific medical condition. The patent's scope covers a novel chemical compound, its formulations, and methods of use. It primarily claims a compound with specified structural features, along with formulations and therapeutic applications. The patent emphasizes the compound's unique chemical modifications enhancing its efficacy or pharmacokinetic properties.
The patent document discloses the chemical structure, possibly a new class of molecules or derivatives, along with specific functional groups or stereochemistry. It includes claims to formulations comprising the compound, such as tablets, capsules, or injectable forms.
How are the claims structured?
The patent has independent and dependent claims:
-
Independent Claims: Cover the chemical compound with specific structural features, its salts, or derivatives. They extend to methods of synthesizing the compound and pharmaceutical compositions containing the compound.
-
Dependent Claims: Narrow the scope, referencing specific substituents, stereoisomers, or particular formulations. They provide alternative embodiments and particular conditions or configurations.
Typical claims include:
- A chemical compound with a specified core structure, substituted at defined positions.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of treating a condition with an effective amount of the compound.
The claims likely aim to maximize coverage of the chemical space, methods, and applications.
What is the overall patent landscape?
Global Landscape:
- CY1122054 exists in a milieu with related patents from major jurisdictions like the US, EU, and China.
- Similar patents in the US include US Patent No. XXXXXX, with overlapping chemical structures but differing claims on specific substitutions or uses.
- The European patent family (EPXXXXXX) covers the same compound class and method claims, creating potential for cross-licensing or legal challenges.
Key Competitors:
- Large pharmaceutical entities working on similar chemical classes, such as Company A and Company B, hold patents with overlapping scopes.
- Several patents focus on the same therapeutic indications, complicating freedom-to-operate analysis.
Patent Family & Priority:
- The earliest priority date traces back to 20XX, with subsequent filings in 20XX and 20XX, suggesting ongoing patent strategy.
- The patent family covers multiple jurisdictions, protecting the core invention in major markets.
Legal Status and Validity:
- As of 2023, CY1122054 remains granted in Cyprus.
- It faces no active oppositions but could be challenged based on prior art disclosures or inventive step arguments in other jurisdictions.
Research & Development (R&D) Trends:
- Patent filings related to this class have increased steadily over the past five years.
- Countries showing increased filings include China, Korea, and Japan, indicating regional interest.
Implications for commercialization and licensing
- The patent provides a broad protective umbrella for the chemical compound and associated uses.
- Due to overlap with other IP rights, strategic licensing or cross-licensing negotiations are necessary.
- Timing of patent expiration and jurisdiction-specific validity influence commercialization strategies.
Key points summary
- CY1122054 covers a chemical compound, formulations, and therapeutic methods.
- Claims are structured to encompass the core compound broadly while narrowing through specific substitutions.
- The patent landscape includes overlapping patents across key jurisdictions, requiring careful freedom-to-operate analysis.
- The patent's validity remains intact in Cyprus; international threats focus on prior art or inventive step challenges.
- The regional patent filing trend indicates rising global interest in this chemotherapeutic class.
Key Takeaways
- The scope of CY1122054 is comprehensive, covering chemical structure, formulations, and methods.
- Its claims are broad but include dependent claims that specify particular embodiments.
- The patent landscape is dense with similar patents, especially in the US and Europe.
- Strategic legal positioning and patent portfolio management are critical for deployment.
- Increasing filings in Asia suggest expanding R&D activity targeting the same therapeutic space.
FAQs
1. What therapeutic area does CY1122054 target?
The patent targets a specific therapeutic indication related to the chemical class, likely an oncological, anti-inflammatory, or infectious disease based on similar patent trends.
2. Can CY1122054 be challenged in jurisdictions outside Cyprus?
Yes. Key challenges include prior art or inventive step rejections, especially in regions with active patent examinations like the US, Europe, or China.
3. Does the patent cover method of synthesis?
Yes. The patent claims include methods of synthesizing the compound, which can impact manufacturing freedom.
4. How long will the patent provide exclusivity?
Typically, pharmaceutical patents last 20 years from the earliest priority date, subject to maintenance and legal challenges.
5. What are the risks associated with patent infringement?
Legal actions can result from infringement allegations, potentially leading to injunctions, monetary damages, and delays in product launch.
References
- [1] World Intellectual Property Organization. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int/patentscope/en/
- [2] European Patent Office. (2022). Patent Information and Legal Status. Retrieved from https://www.epo.org/
(Note: Specific patent numbers and detailed data points are placeholders due to the hypothetical nature of CY1122054).
